Pfizer's fourth-quarter profits exceeded expectations, driven by strong demand for older drugs despite declining COVID-19 ...

Pfizer has fallen behind the pack when it comes to GLP-1 drugs, but the company is still fighting.

Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting earnings this Tuesday before market open. Here’s what ...

Pfizer is almost certain to survive the current headwinds as a business. However, the dividend may not. It will be important ...

Pfizer (NYSE:PFE) agreed to acquire weight loss drug developer Metsera for US$10b, entering the obesity and GLP-1 market. The ...

Pfizer has spent billions of dollars on acquisitions in the past few decades. Its biggest deals include Warner-Lambert, ...

"The winners in life are differentiated from the losers in life because the winners never fall," Albert Bourla says. "The ...

The patent cliff looms large. UBS analyst Michael Yee pointed to roughly "$15-20B in revenues from key drugs losing patent exclusivity" over the next three years, including blockbusters Vyndaquel, ...

The anti-obesity drug market has the potential to be massive, with multiple analysts projecting it may reach at least $100 billion by 2030. As a result, many top healthcare companies are vying for a ...

Pfizer may look cheap with a ~7% yield, but tight free cash flow, patent cliffs, and limited growth raise downside risk. Read ...

Pfizer Inc. has a rare 3-year tariff exemption and margin defense amid global price parity risks. Click here to read an ...